Silexion Therapeutics (SLXN) announced compelling preclinical data demonstrating the efficacy of its next-generation RNAi therapeutic candidate, SIL204, against human pancreatic, colorectal and ...

A high-level overview of Silexion Therapeutics Corp (SLXN) stock. View (SLXN) real-time stock price, chart, news, analysis, analyst reviews and more.

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination The combined company’s shares and warrants are expected to begin trading on Nasdaq under the ...

Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancersCayman Islands, January 13, 2025 -- Silexion Therapeutics Corp. (NASDAQ: ...

Stay up to date on how Silexion Therapeutics Corp (SLXN:XNAS) stock has performed compared to similar stocks in the same industry on a daily, quarterly, and monthly basis.

Review the current Silexion Therapeutics Corp (SLXN:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if SLXN is the best investment for you.

Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA interference (RNAi) therapy, SIL204, showing potent anti-tumor effects across ...

View the latest Silexion Therapeutics Corp. (SLXN) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination MODI'IN, Israel and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Ltd ...